Veradermics Inc
MANEHealthcare|Biotechnology|USA
$119.60
-5.31 (-4.25%)
Tangible Book
$10.46
Clinical Trials (5)
| Trial | Conditions | Phase | Status | Enrollment | Design | Drug |
|---|---|---|---|---|---|---|
| NCT06724614 Efficacy and Safety of VDPHL01 in Males With AGA | Androgenetic Alopecia, AGA | P2P3 | Active | 480 | RCT, Double-blind | VDPHL01, Placebo |
| NCT07146022 Safety and Efficacy of VDPHL01 in Females With Androgenetic Alopecia (AGA) | Androgenetic Alopecia (AGA), Androgenetic Alopecia | P3 | Recruiting | 552 | RCT, Double-blind | VDPHL01 QD, Placebo, VDPHL01 BID, Placebo |
| NCT06972264 Safety and Efficacy of VDPHL01 in Males With AGA | Androgenetic Alopecia, AGA | P3 | Active | 480 | RCT, Double-blind | VDPHL01, Placebo |
| NCT06527365 Safety and Efficacy of VDPHL01 in Males and Females With AGA | Androgenetic Alopecia, AGA | P2 | Active | 70 | Open-label | VDPHL01 |
| NCT05799157 Safety and Efficacy of VDMN-21 Patch in Subjects With Common Warts | Verruca Vulgaris, Warts | P2 | Completed | 153 | RCT, Double-blind | VDMN-21 Patch Low Dose, VDMN-21 Patch High Dose, Vehicle Patch |